Number 729 • March 2018

# Product supply shortages addressed for *Alberta Drug Benefit List (ADBL)*

Alberta Blue Cross has been advised by Apotex Inc. that the shortage for Apo-Lithium Carbonate 150 mg Capsule (DIN 02242837) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **April 23, 2018.** 

#### **LITHIUM CARBONATE**

#### **150 MG CAPSULE**

00002242837	APO-LITHIUM CARBONATE	APX	\$ 0.0667
00002216132	PMS-LITHIUM CARBONATE	PMS	\$ 0.0667
00000461733	CARBOLITH	VCL	\$ 0.1240

Alberta Blue Cross has been advised by Teva Canada Limited that the shortage for Teva-Tryptophan 500 mg Tablet (DIN 02240333) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **April 23, 2018.** 

# L-TRYPTOPHAN

## **500 MG TABLET**

00002248538	APO-TRYPTOPHAN	APX	\$ 0.3563
00002240333	TEVA-TRYPTOPHAN	TEV	\$ 0.3563
00002029456	TRYPTAN	VCL	\$ 0.7755

Alberta Blue Cross has been advised by Pharmascience Inc. that the shortage for pms-Buprenorphine/Naloxone 8 mg/2 mg Sublingual Tablet (DIN 02453916) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **April 23, 2018.** 

# **BUPRENORPHINE HCL / NALOXONE HYDROCHLORIDE DIHYDRATE**

# **8 MG / 2 MG SUBLINGUAL TABLET**

00002453916	ACT BUPRENORPHINE NALOXONE	APH	\$ 1.1825
00002408104	MYLAN-BUPRENORPHINE NALOXONE	MYP	\$ 1.1825
00002424878	PMS-BUPRENORPHINE/NALOXONE	PMS	\$ 1.1825
00002295709	SUBOXONE	IUK	\$ 4.7300

Alberta Blue Cross has been advised by Apotex Inc. that the shortage for Apo-Fluvoxamine 50 mg Tablet (DIN 02231329) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **April 25, 2018.** 

#### **FLUVOXAMINE MALEATE**

#### **50 MG TABLET**

00002255529	ACT FLUVOXAMINE	APH	\$ 0.2105
00002231329	APO-FLUVOXAMINE	APX	\$ 0.2105
00001919342	LUVOX	BGP	\$ 0.9403

Alberta Blue Cross has been advised by Apotex Inc. that the shortage for Apo-Fluvoxamine 100 mg Tablet (DIN 02231330) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **April 25, 2018.** 

#### **FLUVOXAMINE MALEATE**

# **100 MG TABLET**

00002255537	ACT FLUVOXAMINE	APH	\$ 0.3783
00002231330	APO-FLUVOXAMINE	APX	\$ 0.3783
00001919369	LUVOX	BGP	\$ 1.6910

# Removal of temporary benefit from the *Alberta Drug Benefit List (ADBL)*

Due to the shortage of Aldara 5% Topical Cream (DIN 02239505) manufactured by Valeant Canada LP and Apo-Imiquimod 5% Topical Cream (DIN 02407825) manufactured by Apotex Inc., Zyclara 3.75% Topical Cream (DIN 02340445) manufactured by Valeant Canada LP was added as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

Valeant Canada LP has advised Alberta Blue Cross that the shortage of Aldara 5% Topical Cream (DIN 02239505) has been resolved.

As a result, Zyclara 3.75% Topical Cream (DIN 02340445) will no longer be considered a temporary benefit for the *ADBL* **after April 25, 2018.** 

## When you have questions:

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at:

**780-498-8370** (Edmonton and area) • **403-294-4041** (Calgary and area) • **1-800-361-9632** (toll free) **FAX 780-498-8406** (Edmonton and area) • **FAX 1-877-305-9911** (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims. **Visit ab.bluecross.ca/providers/pharmacy-home.php** 



